PRIMARY STUDY
Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis
Key Findings: Ulcerative colitis does not worsen Microbial translocation (MT), inflammation, or immune activation in subjects with HIV infection. Chronic mesalazine treatment appears to have anti-inflammatory properties in the gut. Positive correlations were found between I-FABP and sCD14 (
Type of Study: Clinical Trial
Study Sample Size: 26
Study Result: Inconclusive
Research Location(s): Italy
Year of Pub: 2016
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Citation: Michelini Z, et al. Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis. HIV Clin Trials. 2016; 17:49-54. doi: 10.1080/15284336.2015.1125077
Authors: Michelini Z, Baroncelli S, Fantauzzi A, Pasquale C, Galluzzo CM, Sanchez M, Gatto M, Amici R, Franco M, d'Ettorre G, Fimiani C, Mezzaroma I, Vullo V, Merli M, Palmisano L
